News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|February 4, 2022

Overview and Incidence of Insomnia Disorder

Michael J Thorpy, M.B., Ch.B and Karl Doghramji, MD provide an overview of insomnia, highlighting the incidence and disease burden.

Episodes in this series

EP. 1 Overview and Incidence of Insomnia Disorder

EP. 1 Overview and Incidence of Insomnia Disorder

EP. 2 DSM-V Diagnostic Criteria for Sleep Disorders

EP. 2 DSM-V Diagnostic Criteria for Sleep Disorders

EP. 3 Overview of Parasomnias

EP. 3 Overview of Parasomnias

EP. 4 Treatments for Parasomnia and Sleep Disorders

EP. 4 Treatments for Parasomnia and Sleep Disorders

EP. 5 Disorders and COVID-19

EP. 5 Disorders and COVID-19

EP. 6 Insomnia: Treatment and Management Considerations

EP. 6 Insomnia: Treatment and Management Considerations

EP. 7 Insomnia Clinical Practice Pearls

EP. 7 Insomnia Clinical Practice Pearls

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

concussion

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

brain injury

Restoring Emotional Self-Awareness After Brain Injury: Research Explores Novel Approach

ByDawn Neumann, PhD, FACRM

July 24th 2026

Alzheimer

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

ByLeah Kuntz,Tri Doan, MD, PhD

July 20th 2026

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

ByKsenia Kastanenka, PhD

June 15th 2026

full house

Monoamines: A Full House

ByJohn J. Miller, MD

June 10th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD